Renvio
Renvio sells electronic records, billing and analytics for dialysis organizations, from independent centers and acute dialysis providers to skilled nursing facilities and home therapy programs. Dialysis Manager brings together treatment documentation, prescriptions, laboratory results and care plans for patients on hemodialysis or peritoneal dialysis, with equipment and home treatment interfaces feeding readings into the record. Billing Manager carries the documented encounter into claim preparation, eligibility, authorizations and collections, and Clinic Insights reports on quality and operations across clinics.
The predictive module in Dialysis Manager, launched with model partner Klinrisk in September 2025, flags patients at risk of hospitalization within 30 days, rates them high, medium or low and shows the factors behind each flag in the record where the team reviews orders, documents interventions and tracks next steps. Renvio also offers AI assisted charting and watches for missed treatments and slipping adequacy. In a company analysis of roughly 20,000 dialysis patients, nearly 87% of those labeled high risk were hospitalized within 60 days, with the size of that group and any reduction in hospitalizations from using the tool left out.
Western Nephrology, Concerto Renal Services and SV Healthcare appear among its customers. Renesan and Visonex combined in 2023 with investment led by The Brydon Group and took the Renvio name in 2024; the company is based in Rancho Santa Margarita, California.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Dialysis Manager uses a learned model, built with Klinrisk, to flag dialysis patients at risk of hospitalization, and the score appears with its contributing factors beside the treatment record, where a nurse or nephrologist decides which chart to review and which interventions to document. The prediction depends on the model, while the record itself holds treatments, orders, medication and lab data, and practices run billing, claims and administrative reporting on the same suite. AI assisted charting and embedded clinical guidance add smaller learned features around the core record.
A hospitalization flag prompts the dialysis team to open the chart and the factors behind the risk, and staff update orders, document an intervention and track follow through in the same record. The launch materials keep the nephrologist involved when the software suggests a workflow, including a possible medication review, and the homepage says the AI works without replacing clinical judgment. No numeric threshold for escalating a case is given, nor who receives a flag when the regular team is away, nor what happens after the care team overrides it.
Klinrisk is named as Renvio's partner for hospitalization prediction in the dialysis record, and the output is a high, medium or low rating with contributing factors shown in the workflow, validated in an analysis that tracked later hospitalizations among dialysis patients.
The deployed model version, the full list of training variables, the handling of missing data and the schedule for model updates are not given, and Klinrisk's better documented chronic kidney disease progression model predicts a different outcome.
Klinrisk supplies the predictive AI embedded in Dialysis Manager, Renvio provides the patient record and the interface where the score and its factors appear, and AWS hosts the environment, so the inference partner and the cloud provider are both named. Whether Klinrisk runs a separate inference endpoint, which fields it receives, how long it keeps them and whether it may use them to train or recalibrate a model are not stated.
A Renvio analysis of about 20,000 dialysis patients found that nearly 87% of those it placed in a high risk group were hospitalized within 60 days, while the product page gives the prediction window as 30 days. The size of the flagged group, how scores were assigned and how many admissions the model missed are not given.
The partners announced pilots aimed at avoidable hospitalization, with no measured change in admissions yet, and the AI page's counter for the reduction in hospitalizations shows no figure. Klinrisk's published validation is for a chronic kidney disease progression score, a different endpoint.
The risk module draws on data in Dialysis Manager and shows its flag beside the clinical chart, where clinicians inspect the contributing factors and decide what to document. Renvio trains its EHR staff on HIPAA security and hosts the record in the cloud.
No retention window, training use policy or deidentification process is stated for the prediction product, and neither the route for reporting a wrong prediction nor how data move from the record into Klinrisk's part of the workflow is described.
Renvio's certification page describes HIPAA security training and testing for the EHR development team, and the product processes identifiable treatment records and delivers patient specific risk flags inside Dialysis Manager. Terms and a privacy policy address users of the service, but no business associate agreement covering clinical data processing is reproduced and nothing says the predictive feature falls under one. Whether Klinrisk is treated as a subcontractor, with an agreement reaching the clinical data it handles, is not said.
Clarity, an EHR in the Renvio portfolio, appears on Drummond's certified health IT list, and Renvio cites ONC EHR certification, PointClickCare marketplace status and an AWS SOC 2 report for the Dialysis Manager hosting environment. That cloud report belongs to AWS and covers neither Renvio's own development and operations nor the predictive module and its supplier. No Renvio SOC 2 or ISO certificate is claimed for the dialysis prediction service, so the outside check behind the controls is the federal health IT testing of the EHR.
The AI in Dialysis Manager flags patients at risk of hospitalization within 30 days and is sold to support clinical decisions for people with end stage renal disease. The launch announcement adds intervention support, medication optimization and coordination with the nephrologist, and the AI page says earlier risk identification and structured intervention support help reduce preventable hospitalizations.
Renvio cites health IT certification for its electronic records, and its disclaimers page covers certification costs, data export and multifactor authentication. No FDA clearance, authorized intended use or regulatory exclusion is stated for the risk module.
The risk display shows the factors behind a hospitalization flag, which helps a clinician see why a chart was brought forward. The reported validation covers a combined dialysis population and gives one result for patients the model placed in its high risk group, so nothing shows whether performance varies by age, race, treatment setting or modality. No process is described for bias testing, approving a model version or monitoring performance when a clinic with a different patient population starts using the model.
A treatment team can open a risk flag in the chart, review the factors behind it and record what it decided, a practical way to question an output before changing care. The terms cover how the service is provided and how disputes are handled in general, and they make no promise to investigate or correct a wrong prediction at Renvio's expense, with no error report route for affected patients. The high risk group's hospitalization rate lacks the group size and method needed to check it against a clinic's own outcomes.
The hospitalization flag appears in Dialysis Manager beside the clinical record used to review orders and document interventions. Renvio lists a PointClickCare marketplace connection for skilled nursing work and sends information to the CMS dialysis quality reporting system, and its home therapy offering connects to dialysis machines to bring treatment data into the record. The risk prediction is not shown flowing into a second named EHR in either direction, so the integration depth sits in Renvio's own record and its reporting links.
Dialysis Manager runs as a hosted EHR on AWS, and the terms offer the service to users in the United States, with charting in clinics and remote access for home therapy teams both running on that record. The terms say who may use the service by location without committing where records are stored. The AWS regions, the backup location and whether the hospitalization model runs inside the same boundary as the EHR are not stated.
Dialysis Manager and the rest of Kidney Care Cloud are sold to dialysis organizations through a demonstration and sales conversation, as a full suite or as components for needs such as billing and analytics, and hospitalization prediction is a feature of Dialysis Manager.
No price per user, center or treatment is shown, and whether the predictive features are bundled or charged separately is not said, so a clinic can map the workflows it needs but not the model's added price or implementation fees.
Dialysis Manager supports in center hemodialysis, home hemodialysis and peritoneal dialysis, with offerings for acute dialysis providers and skilled nursing facilities, and those sites use the record for labs, treatments and quality documentation, with machine inputs where available.
The hospitalization prediction is sold for dialysis patients with end stage renal disease, and its one reported result covers a high risk group across the whole analysis, with no breakdown by treatment type or setting, so the chart workflows are more precisely named than the populations where the prediction has been tested.
Alternatives to Renvio
Other products that do the same kind of work as Renvio, and what each one does.
SomaX, from SmartChart Health, is an AI workspace for physicians and nurse practitioners who round in nursing homes, skilled nursing facilities and post acute care, built by a nursing home physician.
HealthVision is Health Data Analytics Institute's platform for predictive risk and chart summarization, built on longitudinal data covering more than 140 million patients and 500 billion encounters over 26 years.
CancerLinQ is ConcertAI's oncology intelligence suite for community practices, cancer centers and health system oncology programs.
Mosai is a care coordination platform for home health agencies, hospices and physician practices, formed when Medalogix and Forcura merged in March 2025 and renamed Mosai in October 2025. medalogix.com now forwards to mosai.com, so anyone searching for Medalogix, its hospice product Muse…
Tyto Care sells remote examination hardware and software that health systems and health plans can deploy with their own clinical teams.
Meditab Software sells Intelligent Medical Software, or IMS, as the electronic record, practice management and billing system for ambulatory teams.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Quote based
|
Dialysis Manager is sold through sales, as a suite or by component; no rate is shown for the predictive feature. | No business associate agreement is offered for the prediction module. | Not published | Vendor Published |
Kidney Care Cloud is offered as a suite or by component, with no price or implementation fee shown for Dialysis Manager or hospitalization prediction.